U.S. Markets open in 1 hr 33 mins
  • S&P Futures

    3,853.75
    +8.75 (+0.23%)
     
  • Dow Futures

    31,154.00
    +58.00 (+0.19%)
     
  • Nasdaq Futures

    13,352.00
    +57.75 (+0.43%)
     
  • Russell 2000 Futures

    2,163.60
    +5.90 (+0.27%)
     
  • Crude Oil

    52.99
    -0.32 (-0.60%)
     
  • Gold

    1,871.70
    +5.20 (+0.28%)
     
  • Silver

    26.00
    +0.24 (+0.93%)
     
  • EUR/USD

    1.2154
    +0.0038 (+0.3160%)
     
  • 10-Yr Bond

    1.0900
    0.0000 (0.00%)
     
  • Vix

    21.29
    -1.95 (-8.39%)
     
  • GBP/USD

    1.3711
    +0.0056 (+0.4100%)
     
  • USD/JPY

    103.4620
    -0.1080 (-0.1043%)
     
  • BTC-USD

    32,640.14
    -861.96 (-2.57%)
     
  • CMC Crypto 200

    648.11
    -31.80 (-4.68%)
     
  • FTSE 100

    6,746.49
    +6.10 (+0.09%)
     
  • Nikkei 225

    28,756.86
    +233.60 (+0.82%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Silk Road Medical, Inc. (SILK) Investigation

·2 min read

NEW YORK, NY / ACCESSWIRE / January 14, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Silk Road Medical, Inc. ("Silk Road" or the "Company") (NASDAQ:SLK). Investors who purchased Silk Road securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/slk.

The investigation concerns whether Silk Road and certain of its officers and/or directors have violated federal securities laws.

On January 13, 2021, Silk Road announced in a U.S. Securities and Exchange Commission filing that the Company was "voluntarily recalling 288 units of our ENROUTE® Transcarotid Stent System, or ENROUTE SDS, based on five reports we received related to the tip of the stent delivery system becoming detached in five TCAR procedures. These reports were made between September 2020 and January 2021 and we have commenced an investigation into this matter." On this news, Silk Road's stock price fell $4.22 per share, or 7.12%, to close at $55.02 per share on January 13, 2021.

If you are aware of any facts relating to this investigation, or purchased Silk Road shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/slk. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/624320/Bronstein-Gewirtz-Grossman-LLC-Notifies-Shareholders-of-Silk-Road-Medical-Inc-SILK-Investigation